Stock thesis
Recursion Pharmaceuticals-A
Start with the strongest observed signals, the evidence that could challenge them, and the next source-backed checks.
RECURSION PHARMACEUTICALS-A (RXRX) is an equity security tracked from 13F filings in the seeded stock universe.
Neutral synthesis
Research orientation
Observed facts, not a rating
Why this name is here
Observed evidence
3 tracked funds report RXRX in their latest available 13F,
representing $166.1M of combined reported value on this page.
- 2 funds report a new or increased share count in a comparable filing.
- 0 funds report it at 5% or more of the portfolio.
Counter-evidence
What could change the view
No lower or absent reported position appears in the comparable filings on this page. Missing prior quarters can also make change unavailable.
- 13F positions are delayed and exclude short positions and many non-US assets.
- Financial, insider, earnings, or volatility evidence may be missing or point in another direction.
Continue the work
Next research checks
13F holders
Rows are narrowed by movement, fund type, and position size.
3 holders
No holders match this filter.
Try another movement slice or return to the full holder table.
Show all holders
SEC fundamentals
Financials
Companyfacts
No published earnings analysis yet
We publish a cited report after an eligible official earnings filing is accepted and passes validation.
